Texas Oncology and Aetna partnered to provide a practice-based program that reduced costs while maintaining adherence to treatment pathways and patient satisfaction in Medicare patients.
Bobby Daly, MD, MBA, and Ray D Page, DO, PhD, discuss the ramifications of clinical pathway vendor conflicts of interest and the potential issues of full transparency on the part of committee members.
Precision oncology strategies may improve overall survival for patients with refractory cancer while lowering the average per-week health care costs, resource utilization, and end-of-life costs.
Panelists shared their strategies of enhancing care coordination for patients in the transition toward value-based care planning.
The advantages of implementing technology into the daily operations of a community-based practice vary from finding inefficiencies in operational processes for identifying gaps to optimizing value-based care.
A session highlighted strategies for managing clinical trials for cancer and improving patient accrual in the community setting.
Younger patients who received certain chemotherapies for solid tumors or leukemia may not have T-cells capable of becoming effective CAR T-cells.
A recent literature review analyzed the alternative payment models used in the real world and how they have affected the quality of oncology care.
Widespread use of alternative payment models may improve the quality of breast and colorectal cancer screening programs.
The US government said on Friday it will pay for certain genetic tests for Medicare-eligible patients with advanced cancer, in a bid to help match patients with the drugs most likely to provide benefit.